Company intelligence / Profile preview

Institute for Life Changing Medicines

Stamford, Connecticut, United Stateslifechangingmedicines.org ↗
Ownership
Private
Development stage
Other
01

Overview

The Institute is initiating clinical development of its first program (mRNA-3351 for Crigler-Najjar Syndrome Type 1); other programs are in planning or development stages[3][4].

Therapeutic areas
Rare Diseases
Modalities
mRNA-based drugsGene therapyCell therapy
Industry
Academic Hospital/University/Research
02

Partnerships

Beyond the preview

Go deeper on Institute for Life Changing Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Institute for Life Changing Medicines.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call